Formulary guidance and transparency from P&T to point of care


Reality Check on Growth Hormones

Market access for growth hormone treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: More than 60% of covered lives under the pharmacy benefit in commercial formularies and health exchange programs have some type of utilization management restriction  
  • Class Trends: Effective Jan. 1, 2019, CVS Health Corp. is returning Genotropin to its 2019 Standard Control Formulary
  • Key Findings: The market is trending toward the development of long-acting growth hormone drugs that can be administered weekly or biweekly instead of currently marketed daily growth hormones 

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.